SCHEMBL6172499

SCHEMBL6172499

COC(=O)N(c1cc(N)ccc1C(=O)Nc1ccc2ccn(C(=O)OC(C)(C)C)c2c1)C1CCN(c2ccncc2)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 8/20 0.35
GPR119 Q8TDV5 3/20 0.34
MAPK14 Q16539 1/20 0.33
PTPN11 Q06124 1/20 0.33
PIK3CD O00329 1/20 0.32
ABL1 P00519 1/20 0.32
EGFR P00533 1/20 0.32
HCK P08631 1/20 0.32
SRC P12931 1/20 0.32
KDR P35968 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
MTOR P42345 1/20 0.32
PIK3CG P48736 1/20 0.32
EPHB4 P54760 1/20 0.32
PRKDC P78527 1/20 0.32
PI4KB Q9UBF8 1/20 0.32
MAPT P10636 3/20 0.32
MEN1 O00255 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7089068 0.90 GPR119 (0.36) F10GPR119MAPK14SMN1; SMN2
SCHEMBL6169102 0.89 F10 (0.39) F10MAPTMEN1KMT2A
SCHEMBL6171243 0.89 GPR119 (0.36) F10GPR119MAPK14PTPN11MAPT
SCHEMBL6171248 0.84 F10 (0.43) F10
SCHEMBL6168512 0.83 F10 (0.45) F10
SCHEMBL6169049 0.81 F10 (0.38) F10GPR119MAPK14
SCHEMBL6170084 0.79 GPR119 (0.36) F10GPR119MAPK14
SCHEMBL6171172 0.78 F10 (0.38) F10GPR119MAPTMEN1KMT2A
SCHEMBL6169725 0.78 F10 (0.39) F10MAPT
SCHEMBL7082624 0.78 F10 (0.45) F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1019045-B1 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2005-06-08 EP disclosed
US-20030078431-A1 Antithrombotic agents BEIGHT DOUGLAS WADE (US) 2003-04-24 US disclosed
US-6500851-B2 ANTICOAGULANT IN MAMMLS ELI LILLY AND COMPANY 2002-12-31 US disclosed
US-20020173518-A1 Antithrombotic agents BEIGHT DOUGLAS WADE (US) 2002-11-21 US disclosed
US-6372759-B1 BLOOD COAGULATION FACTOR XA FOR MAMMALS ELI LILLY AND COMPANY 2002-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173518-A1 Antithrombotic agents SERPINC1, TFPI, F11 F10 15/4885GPR119 1388/4885MAPK14 1019/4885
US-20030078431-A1 Antithrombotic agents SERPINC1, TFPI, F11 F10 15/4885GPR119 1388/4885MAPK14 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.